Genomic Features of Response to Combination Immunotherapy in Lung Cancer

Publication date: 14 May 2018 Source:Cancer Cell, Volume 33, Issue 5 Author(s): Martin Früh, Solange Peters In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer. Teaser In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research